Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...

Neurofibromatosis type 1 (NF1) is the most common of the three types of neurofibromatosis ... focuses on early detection of treatable complications. This often includes surgery to remove or reduce the ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational ... Historically, surgery has been the primary option for NF1 but leads to life-altering ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

A multicenter collaboration led by the Bellvitge Biomedical Research Institute (IDIBELL) - Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) identified a ...

Adam Pearson used his neurofibromatosis struggles to succeed in acting and advocacy, inspiring others to accept differences ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The findings have been published in the journal Clinical Cancer Research.

This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib.

Neurofibromatosis type 1 (NF1), specifically ... to come forward and seek help as there are options of medication or surgery which do not cure the disease, but at least can improve the quality ...

The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for adults and children aged 2 and older with ...